When should the β-blocker window in cirrhosis close?

Affiliations

¹ Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California.
² Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: barunyon@mednet.ucla.edu.

Editorial

Phillip S Ge et al. Gastroenterology. 2014 Jun.

. 2014 Jun;146(7):1597-9.

doi: 10.1053/j.gastro.2014.04.028. Epub 2014 Apr 23.

¹ Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California.
² Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: barunyon@mednet.ucla.edu.

No abstract available

Comment on

Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.
Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, Hagmann M, Blacky A, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Reiberger T. Mandorfer M, et al. Gastroenterology. 2014 Jun;146(7):1680-90.e1. doi: 10.1053/j.gastro.2014.03.005. Epub 2014 Mar 12. Gastroenterology. 2014. PMID: 24631577